Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

Quoin Pharmaceuticals (NASDAQ: QNRX) will provide a corporate update and release fourth quarter and full-year 2025 financial results before the market opens on Thursday, March 26, 2026.

Rhea-AI Summary

Quoin Pharmaceuticals (NASDAQ: QNRX) will provide a corporate update and release fourth quarter and full-year 2025 financial results before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025, per the company.

Argus Mar 19 session

+5.36% close to close Open Argus

Details

News Market Reaction – QNRX

In the Mar 19 session, QNRX gained 5.36%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with hei...

Analysis

The stock moved +5.4% in the session following this news. A strong positive reaction aligns with heightened interest ahead of the scheduled Q4 and full-year 2025 update. The company has recently delivered several regulatory and clinical milestones, including Fast Track status on Mar 11, 2026, which framed expectations entering this event. However, prior news sometimes saw mixed follow-through, so investors may have weighed dilution capacity from registered ADS resales and broader biotech volatility when assessing sustainability of any large gain.

Key Figures

Earnings release date: March 26, 2026 Fiscal year end: December 31, 2025

Earnings release date

March 26, 2026

Scheduled Q4 and full-year 2025 results release before market open

Fiscal year end

December 31, 2025

Full-year 2025 period to be reported

Historical Context

5 past events · Latest: Mar 11

5 events

1. Mar 11

   Fast Track designation

   24h Move

   -1.1%

   FDA granted Fast Track status to QRX003 for Netherton Syndrome.

2. Feb 26

   Awareness campaign

   24h Move

   +0.1%

   NETHERTON NOW campaign update highlighting growing disease awareness metrics.

3. Jan 27

   Japan ODD submission

   24h Move

   -1.7%

   Submission for Orphan Drug Designation and Fast Track review in Japan.

4. Jan 20

   Saudi breakthrough filing

   24h Move

   +1.8%

   Filed for Breakthrough Medicine Designation for QRX003 in Saudi Arabia.

5. Nov 11

   Pipeline expansion

   24h Move

   +41.4%

   Reported achieving target rapamycin loadings and plans for new clinical trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025.

About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Quoin Pharmaceuticals (QNRX) release its Q4 and full-year 2025 results?

Quoin will release Q4 and full-year 2025 results before the market opens on March 26, 2026. According to the company, the release includes an operational update and financial highlights for 2025.

What will Quoin Pharmaceuticals (QNRX) cover in its March 26, 2026 corporate update?

The corporate update will cover operational achievements, recent accomplishments, and 2025 financial highlights. According to the company, the presentation pairs an operational update with the fourth quarter and full-year financial results.

How can investors access Quoin Pharmaceuticals (QNRX) March 26, 2026 announcement?

Investors can access the March 26 announcement via Quoin's investor channels around the market open time. According to the company, results and the corporate update will be released before market open on that date.

Will Quoin Pharmaceuticals (QNRX) provide clinical program updates on March 26, 2026?

Yes, the company indicated the operational update will highlight recent accomplishments, which may include clinical program updates. According to the company, the operational update will summarize key achievements from the quarter.

What date covers the financial results Quoin (QNRX) will report on March 26, 2026?

The financial results cover the fourth quarter and full year ended December 31, 2025. According to the company, both quarter and full-year 2025 financial highlights will be disclosed in the release.

Is the Quoin Pharmaceuticals (QNRX) March 26, 2026 release expected before trading begins?

Yes, the company will release information before the market opens on March 26, 2026. According to the company, the timing is intended to precede the trading day and include operational and financial highlights.